Stem cell treatments are being offered in Indian clinics although preclinical evidence of their efficacy and safety is lacking. This is attributed to a governance vacuum created by the lack of legally binding research guidelines. By contrast, this paper highlights jurisdictional ambiguities arising from trying to regulate stem cell therapy under the auspices of research guidelines when treatments are offered in a private market disconnected from clinical trials. While statutory laws have been strengthened in 2014, prospects for their implementation remain weak, given embedded challenges of putting healthcare laws and professional codes into practice. Finally, attending to the capacities of consumer law and civil society activism to remedy the problem of unregulated treatments, the paper finds that the very definition of a governance vacuum needs to be reframed to clarify whose rights to health care are threatened by the proliferation of commercial treatments and individualized negligence-based remedies for grievances.

The government of India has heavily promoted research and development in regenerative medicine together with domestic innovation and business development initiatives. Together, these promise a revolution in healthcare and public empowerment in India. Several national and transnational linkages have emerged to develop innovative capacity, most prominently in stem cell and cord blood banking, as well as in gene therapy, tissue engineering, biomaterials and 3D printing. However, challenges remain of achieving regulatory oversight, viable outputs and equitable impacts. Governance of private cord blood banking, nanomaterials and 3D bioprinting requires more attention. A robust social contract is also needed in healthcare more generally, so that participation in research and innovation in regenerative medicine is backed up by treatments widely accessible to all.

No abstract

Due to anthropogenic activities and natural abundance, lead exposure is a common phenomenon. Neurotoxic and genotoxic effects of lead are widely known. Recent studies have suggested that lead exposure can affect young generation and transfer to the progeny thus posing a great threat for future generation. The present study was focused on lead toxicity in terms of locomotion and growth of Caenorhabditis elegans (N2 wild type) at three sub-lethal doses (3µM, 15 µM and 30 µM) of Pb (NO3)2 for 24 hours (sub-chronic exposure). Caenorhabditis elegans is a nematode with an established eco- toxicity marker model organism, due to its short life cycle and ease to monitor. After lead  exposure, significant toxic manifestations were observed in locomotion of the nematode in terms of omega bends (+350% for 30 µM exposure dose, p<0.001), reversals (-26.98%, -49% and -66.35% for 3 µM, 15 µM and 30 µM exposure doses respectively, p<0.001), turn counts (-38.66%, -62.61% and -81.93% for 3 µM, 15 µM and 30 µM exposure doses respectively, p<0.001 ) and peristaltic speed alterations (+97.83%, +225.92% and +454.63% for 3 µM, 15 µM and 30 µM exposure doses respectively, p<0.001). Successive reduction in the body length at lower doses shows remarkable toxic alterations in nematodes. The obtained data may be useful to extrapolate the effects of lead exposure on humans, as many of the similar pathways and cellular processes affected by Pb in humans are also present in C. elegans.

No abstract